Medicare Coverage for Gout: Medications, Joint Injections, and Pegloticase Infusions

Gout is the most common form of inflammatory arthritis in the United States, affecting an estimated six to eight million Americans — and the prevalence climbs sharply with age. Among Medicare beneficiaries over 65, gout affects roughly 9 to 12 percent of men and 3 to 5 percent of women. For most patients, gout begins as episodic acute attacks of excruciating joint pain, swelling, and redness that resolve in days or weeks. But when hyperuricemia goes undertreated for years, the disease progresses to chronic tophaceous gout — with urate crystal deposits visible under the skin, permanent joint damage, and functional disability.

Medicare covers the full range of gout management: diagnostic laboratory tests and imaging under Part B, acute flare treatment through joint injections (also Part B), and the entire spectrum of gout medications under Part D. For patients with severe refractory gout, Medicare Part B also covers pegloticase (Krystexxa), a biologic infusion that can cost more than $200,000 per year at list price — making supplement coverage decisions the single most consequential financial question a gout patient on Medicare can face.

What Is Gout and Why It Peaks at Medicare Age

Gout develops when serum uric acid concentrations remain elevated (hyperuricemia) long enough for monosodium urate crystals to deposit in and around joints, bursae, and soft tissues. The kidneys clear approximately two-thirds of uric acid produced by the body; when they can’t keep pace — because production is high, excretion is low, or both — urate builds up and crystallizes.

The disease progresses in recognizable stages:

• Asymptomatic hyperuricemia: Serum uric acid elevated above the physiologic saturation threshold (~6.8 mg/dL) but no symptoms yet. Many patients remain here for years.
• Acute gout flares: Sudden onset of severe joint pain, typically starting in the big toe (podagra), ankle, knee, or wrist. Attacks peak within 12–24 hours, last 3–10 days without treatment, and may resolve completely — leaving a deceivingly pain-free intercritical period.
• Intercritical periods: Asymptomatic intervals between attacks. Crystals remain in the joint; without treatment, flares become more frequent and involve more joints.
• Chronic tophaceous gout: Years of untreated hyperuricemia produce tophi — visible urate deposits under the skin of the ears, elbows, fingers, and Achilles tendon — and irreversible joint erosion.

Several factors common in the Medicare population drive elevated uric acid. Diuretic use is among the most important: both thiazide diuretics (hydrochlorothiazide, chlorthalidone) and loop diuretics (furosemide) significantly raise serum uric acid by reducing renal urate excretion. Hypertension requiring diuretics is near-universal in older adults. Chronic kidney disease impairs urate clearance through the same mechanism — reduced GFR means reduced uric acid excretion. Insulin resistance and type 2 diabetes reduce renal urate excretion directly; gout and metabolic syndrome are closely intertwined. Purine-rich foods — organ meats, red meat, shellfish, high-fructose corn syrup, and alcohol (especially beer and spirits) — raise uric acid production. Men, who have naturally higher uric acid levels than premenopausal women, lose that relative protection after women reach menopause — closing the gap at exactly the age when Medicare eligibility begins.

Gout, Uric Acid Kidney Stones, and Kidney Disease

Gout and kidney stones are closely linked conditions that often co-occur in Medicare-age patients. Uric acid stones account for roughly 8 to 10 percent of all kidney stones — and virtually every patient with uric acid stones has elevated uric acid, with or without clinical gout. The mechanisms overlap: low urine pH (common in metabolic syndrome and diabetes) causes uric acid to crystallize in the urine; chronically elevated serum uric acid provides the substrate. Uric acid stones are radiolucent on standard X-ray but visible on CT — a key diagnostic point. They dissolve with urine alkalinization using potassium citrate, unlike calcium stones. If you have both gout and kidney stones, the treatment of your hyperuricemia is also your stone prevention. See Medicare coverage for kidney stones for the full picture of stone procedures and prevention drugs.

Chronic hyperuricemia also damages the kidney directly. Urate crystals deposit in renal tubules and interstitium, contributing to interstitial nephropathy and CKD progression — particularly when gout has been undertreated for years. Conversely, CKD worsens gout by reducing urate excretion. Managing both conditions simultaneously requires coordination between your rheumatologist and nephrologist, and dosing adjustments for allopurinol are critical in CKD to reduce the risk of allopurinol hypersensitivity syndrome. See Medicare and chronic kidney disease for how CKD affects your Medicare cost-sharing.

Part B: Diagnosing Gout

Medicare Part B covers the diagnostic workup for gout when ordered by a physician:

Serum uric acid (CPT 84550): The standard screening and monitoring test. A value above 6.8 mg/dL represents supersaturation. Crucially, serum uric acid can be normal or even low during an acute flare — the inflammatory response mobilizes urate from joints — so a normal value during a flare does not rule out gout. Medicare covers this lab test as part of a medically necessary evaluation; with Medigap Plan G, you owe $0 after the Part B deductible.

Synovial fluid aspiration and analysis (arthrocentesis, CPT 20610 for large joints such as knee; CPT 20605 for intermediate joints; CPT 20600 for small joints; CPT 89060 for polarized light microscopy): The definitive diagnostic test for gout is finding needle-shaped, negatively birefringent monosodium urate crystals in synovial fluid under polarized light microscopy. Arthrocentesis — inserting a needle into the joint to withdraw fluid — is both diagnostic and therapeutic. Draining an acutely inflamed, swollen joint reduces pressure, provides immediate pain relief, and gives a definitive crystal identification. Medicare Part B covers the procedure and the lab analysis. Your cost is 20% of the Medicare-approved amount after the Part B deductible; Medigap Plan G covers that 20%.

Dual-energy CT (DECT): An advanced CT technique that identifies monosodium urate deposits in and around joints based on their unique dual-energy absorption characteristics. DECT is particularly useful in patients where arthrocentesis is inconclusive or the joint is not easily accessible. Medicare covers DECT when medically necessary, typically requiring a specific indication (suspected gout in an inaccessible joint, monitoring tophus burden during treatment).

Standard X-rays: Useful in established chronic gout to identify “rat bite” erosions — the classic punched-out juxta-articular bone defects with overhanging edges — and to rule out other causes of joint disease. X-rays are covered under Part B.

Part B: Corticosteroid Joint Injections for Acute Flares

When an acute gout attack involves a single accessible large joint — particularly the knee — corticosteroid injection is one of the fastest and most effective treatments available. Medicare Part B covers the procedure:

How it works: The physician first aspirates the swollen joint (removing inflammatory fluid), then injects a corticosteroid such as triamcinolone acetonide or methylprednisolone directly into the joint space. The joint aspiration (CPT 20610 for knee/hip) and the injection of the steroid (which may use the same CPT code or an additional injection code) are covered under Part B. Many rheumatologists and orthopedists use ultrasound guidance (CPT 76942) for accuracy, particularly for smaller or deeper joints; Medicare covers ultrasound guidance as well.

Your cost: You pay 20% of the Medicare-approved amount after the Part B deductible ($257 in 2026). A corticosteroid joint injection in an outpatient or office setting typically generates a physician fee of $100–$200 at Medicare rates; 20% is $20–$40. Facility fees are additional if the procedure is done at a hospital outpatient department rather than a physician office.

For patients with polyarticular gout (multiple joints flaring simultaneously) who cannot use NSAIDs or colchicine, systemic corticosteroids (oral prednisone or IM methylprednisolone) are the standard alternative — these are covered under Part D (oral prednisone) or Part B (intramuscular injection in a physician office).

Part B: Pegloticase (Krystexxa) Infusions for Severe Refractory Gout

For patients with chronic refractory gout — defined as gout that has failed or is contraindicated with conventional urate-lowering therapy — Medicare Part B covers pegloticase (Krystexxa), one of the most expensive drugs in rheumatology.

What pegloticase is: Pegloticase is a PEGylated recombinant mammalian uricase — an enzyme that converts uric acid to allantoin, a much more soluble compound that the kidneys excrete easily. Humans lack uricase naturally; pegloticase provides the enzymatic activity we don’t have. It can reduce serum uric acid from, say, 9–12 mg/dL to near zero within hours of the first infusion — and sustained treatment dissolves tophi over months. For patients who have waited years for relief from chronic tophaceous gout, this is transformative.

Who qualifies for Medicare coverage: FDA approval and CMS coverage require that pegloticase be used for chronic gout refractory to conventional therapy. In practice, this means documented failure of or contraindication to allopurinol and febuxostat at maximally tolerated doses. Prior authorization is nearly universal under both Original Medicare advantage plans and Medicare Advantage — the authorization process typically requires a rheumatologist’s documentation of the treatment history, serum uric acid levels, and tophus burden.

Dosing: 8 mg IV every two weeks. A full treatment course to achieve tophus resolution typically takes 6–12 months, or up to 24 months for large tophus burden. The theoretical maximum annual exposure is 26 infusions per year.

Why it’s Part B: Pegloticase is administered by IV infusion in a physician office, hospital outpatient infusion center, or infusion suite — it cannot be self-administered. Drugs given in medical settings that cannot practically be self-administered are classified as Part B drugs, not Part D. This classification matters enormously for cost.

The cost equation without Medigap:

• Medicare-approved rate for pegloticase: approximately $6,000–$10,000 per infusion
• Patient responsibility at 20% coinsurance: $1,200–$2,000 per infusion
• At 26 infusions per year: $31,000–$52,000 per year in coinsurance alone
• Part B has no annual out-of-pocket cap in Original Medicare — exposure is unlimited

The cost equation with Medigap Plan G:

• After the $257 annual Part B deductible, Medigap Plan G pays 100% of Part B coinsurance
• Your total annual cost for pegloticase infusions: $257 (the deductible, paid once)
• This is the single most financially consequential reason to carry Medigap Plan G if you have severe gout

See Medigap plan comparison and Medicare Supplement vs. Advantage costs for a detailed Plan G comparison.

The methotrexate co-treatment protocol: A major advance in pegloticase treatment over the past several years is the addition of low-dose oral methotrexate (15 mg/week) started two to four weeks before the first pegloticase infusion. Anti-drug antibodies against pegloticase cause the drug to lose effectiveness — when antibodies form, they accelerate pegloticase clearance, uric acid rebounds, and infusion reactions become more likely. The original clinical trials showed a response rate of approximately 40% with pegloticase alone. Studies using the methotrexate co-treatment protocol have shown response rates of 70–80% — roughly doubling the chance of sustained tophus clearance. Methotrexate is a Part D drug; generic methotrexate is typically Tier 1 or Tier 2, costing $10–$30/month.

Monitoring during treatment: Serum uric acid is checked before each infusion. If the level rises above 6 mg/dL — indicating loss of pegloticase efficacy from antibody formation — the infusion should not be given, because the drug is no longer enzymatically active and only the PEG component is present to trigger infusion reactions. This uric acid monitoring protocol is standard of care and is a covered Part B lab test.

Part D: Acute Gout Flare Medications

The three medication classes used to treat acute gout attacks are all covered under Medicare Part D:

Colchicine: The FDA-approved low-dose colchicine regimen (1.2 mg immediately, then 0.6 mg one hour later) is highly effective when started within the first 12–24 hours of a flare. For ongoing prophylaxis during urate-lowering therapy initiation, 0.6 mg once or twice daily for three to six months prevents flares that commonly occur as crystals begin to dissolve. Generic colchicine (0.6 mg tablets) is available at most pharmacies. The brand Colcrys, which once held exclusivity pricing at $200–$300/month, faces generic competition; generic colchicine now costs $15–$30/month at most pharmacies. If your Part D plan places colchicine on a higher-cost tier, the IRA $2,100 annual Part D out-of-pocket cap protects you — your maximum total Part D spending cannot exceed $2,100 in 2026.

NSAIDs: Indomethacin (25–50 mg three times daily) and naproxen are the traditional NSAID choices for acute gout. Both are available as generics at very low cost (often under $10 for a course). However, NSAIDs require caution in patients with CKD, peptic ulcer disease, heart failure, or who are on anticoagulants — all conditions that are common at Medicare age. If your kidney function is impaired (eGFR below 30), NSAIDs are generally contraindicated.

Oral corticosteroids: Prednisone (30–40 mg/day for 3–5 days) or a methylprednisolone dose pack is the standard alternative when both colchicine and NSAIDs are contraindicated. Generic prednisone is typically Tier 1, costing $5–$10 for a short course. No significant organ-system contraindications limit corticosteroids in gout (though blood sugar will rise in people with diabetes), making them a reliable fallback.

Part D: Urate-Lowering Therapy

Preventing future gout attacks requires reducing serum uric acid to below 6.0 mg/dL (below 5.0 mg/dL for patients with tophi), and keeping it there indefinitely. Two medication classes accomplish this under Part D:

Allopurinol: The most commonly prescribed urate-lowering drug and the standard first-line agent. Allopurinol is a xanthine oxidase inhibitor — it reduces uric acid production by blocking the enzyme that converts hypoxanthine and xanthine to uric acid. Generic allopurinol (100 mg and 300 mg tablets) is extremely inexpensive — typically $5–$15/month at Tier 1 or Tier 2 on most Part D formularies. Starting dose is typically 100 mg daily, titrated upward over weeks to months until the uric acid target is reached; some patients require 400–600 mg daily.

Important caveats: Allopurinol should never be started during an acute flare — it can paradoxically prolong or worsen the attack. Always start after the flare resolves, ideally with colchicine prophylaxis in place. In CKD, dose reduction is required (typically 100 mg/day for eGFR 30–59, with caution below that), because allopurinol metabolites accumulate and can trigger allopurinol hypersensitivity syndrome (AHS) — a rare but potentially fatal rash and multi-organ reaction. Patients of Southeast Asian and Han Chinese ancestry may carry the HLA-B*58:01 allele that substantially increases AHS risk; genetic testing before starting allopurinol is recommended for these populations.

Febuxostat (Uloric): A second xanthine oxidase inhibitor, approved as an alternative for patients who cannot tolerate allopurinol. Generic febuxostat is available and typically costs $30–$60/month at Tier 2; brand Uloric remains on the market at a much higher price. The FDA added a black box warning in 2019 after the CONFIRMS trial showed a higher rate of cardiovascular death with febuxostat compared to allopurinol, although subsequent analyses have been nuanced. Current guidelines recommend allopurinol first-line; febuxostat when allopurinol is genuinely contraindicated or not tolerated. If your plan places brand Uloric on a specialty tier, the $2,100 IRA cap limits your total Part D annual exposure. See Medicare Part B vs. Part D drug coverage for more on how drugs are categorized between programs.

Managing Gout Alongside Other Conditions

Several comorbidity management decisions affect gout in Medicare-age patients:

Diuretics and uric acid: If you developed gout after starting a thiazide or loop diuretic for hypertension or heart failure, ask your cardiologist or internist whether switching to a non-diuretic antihypertensive is feasible. Losartan (an ARB, also available as a generic for ~$10/month) is the only common antihypertensive that has a mild uricosuric effect — it lowers uric acid modestly and is a reasonable substitution for hydrochlorothiazide in well-controlled hypertension. However, if the diuretic is essential for fluid management in heart failure, urate-lowering therapy is the better solution rather than stopping the diuretic.

Gout and diabetes: The relationship between gout and type 2 diabetes runs through insulin resistance — the same metabolic pathway that impairs renal urate excretion also causes glucose intolerance. Improving metabolic control, losing weight, and reducing alcohol and fructose intake lower uric acid as well as blood sugar. GLP-1 receptor agonists (like semaglutide/Ozempic, covered by Part D for T2D) reduce body weight significantly and may improve uric acid levels as a secondary effect. See Medicare coverage for Ozempic and weight management and Medicare and diabetes for coverage details.

Low-income beneficiaries: Patients who qualify for the Extra Help/Low-Income Subsidy program pay significantly reduced Part D copays — as little as $4.50 for Tier 1 generics in 2026. Generic allopurinol and generic colchicine are accessible at near-zero cost under Extra Help. See Medicare Savings Programs and Extra Help for eligibility and how to apply.

Medigap vs. Medicare Advantage: The Gout Cost Comparison

Original Medicare with Medigap Plan G: The most protective coverage for gout patients who may need pegloticase infusions. After the $257 annual Part B deductible, Plan G covers 100% of Part B coinsurance — meaning joint injections, diagnostic infusions, DECT scans, and pegloticase are all covered. Part D costs for generics (allopurinol, colchicine, prednisone) are minimal.

Medicare Advantage: Plans typically offer lower monthly premiums but require prior authorization for specialist-level gout care. Pegloticase requires pre-authorization with documentation of failed conventional therapy. Step therapy protocols — requiring documented trials of allopurinol and febuxostat before approving pegloticase — are standard. Administrative delays can mean months of waiting while tophaceous disease progresses. Patients who eventually get pegloticase under MA plans may have cost-sharing caps that limit exposure, but the prior authorization burden is significant.

For patients with mild intermittent gout who only need generic allopurinol and occasional colchicine, Medicare Advantage is a reasonable financial choice. For patients with chronic tophaceous gout who are likely candidates for pegloticase, Medigap Plan G’s unlimited Part B coinsurance coverage makes it the strongly preferred option. See Medicare Supplement vs. Advantage cost comparison for a full framework.

Gout Treatment Cost Summary

Seven-Step Gout Management Planning Guide for Medicare Patients

Step 1: Get a definitive diagnosis. Don’t assume a painful, swollen joint is gout — arthrocentesis with crystal analysis is the gold standard. Pseudogout (calcium pyrophosphate deposition disease) looks identical clinically but requires different management. Part B covers the procedure.

Step 2: Know your uric acid baseline. Have serum uric acid measured between attacks (not during a flare, when levels may be falsely normal). Your treatment target is below 6.0 mg/dL for uncomplicated gout, below 5.0 mg/dL for tophaceous disease. Track it at every primary care or rheumatology visit.

Step 3: Start urate-lowering therapy and prophylaxis together. When your rheumatologist starts allopurinol, also start low-dose colchicine prophylaxis for three to six months. Starting ULT without prophylaxis commonly triggers a flare in the first weeks as crystals begin to mobilize — this is the main reason patients stop their allopurinol prematurely. Part D covers both drugs.

Step 4: Choose your Medicare coverage based on your gout severity. If you have or may develop tophaceous gout, Medigap Plan G dramatically reduces your financial risk from pegloticase. Make this decision at enrollment — open enrollment periods have restrictions on late entry. See what is Medicare Part B for enrollment timing.

Step 5: Evaluate your diuretic and review your medication list. Ask your physician whether any current medication may be raising your uric acid — thiazides, loop diuretics, aspirin, niacin, cyclosporine, and tacrolimus all raise uric acid. If a substitution is clinically safe, switching diuretics or lowering aspirin dose may reduce the urate-lowering therapy dose needed.

Step 6: If you need pegloticase, push for the methotrexate co-treatment protocol. The evidence for methotrexate co-treatment is compelling — it nearly doubles the response rate and the increase in cost (generic methotrexate) is minimal. Discuss this with your rheumatologist before starting pegloticase.

Step 7: Apply for Extra Help if cost is a barrier. Generic allopurinol and generic colchicine are extremely affordable under the Extra Help/LIS program. If you have limited income and assets, the subsidy is free to apply for through Social Security. See Medicare Savings Programs.

Frequently Asked Questions

Does Medicare cover Krystexxa (pegloticase) for gout? Yes. Medicare Part B covers pegloticase as an infused biologic drug for chronic refractory gout — meaning gout that has failed or is contraindicated with conventional urate-lowering therapy. Prior authorization is typically required. Without a Medigap supplement, the 20% Part B coinsurance on each infusion can total $31,000–$52,000 per year at maximum dosing. Medigap Plan G covers all Part B coinsurance after the annual deductible.

Is colchicine covered under Medicare Part D? Yes. Generic colchicine (0.6 mg tablets) is covered under Medicare Part D at most formularies. It is typically Tier 1 or Tier 2, costing $15–$30/month. The brand Colcrys is also covered but at a higher tier; ask your pharmacy to substitute the generic. The IRA $2,100 annual Part D out-of-pocket cap applies if colchicine is placed on a high-cost tier.

What’s the difference between Part B and Part D gout coverage? Part B covers services performed in medical settings: diagnostic lab tests, joint aspirations, corticosteroid injections, and pegloticase infusions (which cannot be self-administered). Part D covers self-administered oral medications: colchicine, allopurinol, febuxostat, NSAIDs, and prednisone. Understanding this split matters because Part B coinsurance is unlimited in Original Medicare, while Part D has the $2,100 annual cap. See Medicare Part B vs. Part D drugs for more detail.

Can gout cause kidney disease? Yes. Chronic hyperuricemia can damage the kidney directly through urate crystal deposition in tubules and interstitium — a condition called gouty nephropathy. Additionally, uric acid kidney stones (radiolucent stones that dissolve with potassium citrate) are more common in patients with gout. Managing uric acid levels with allopurinol or febuxostat protects kidney function as well as joints. Conversely, CKD worsens gout by reducing urate excretion. See Medicare and chronic kidney disease.

What happens if I have Medicare Advantage and need pegloticase? Medicare Advantage plans cover pegloticase but typically require prior authorization and often impose step therapy requirements — meaning you must document failed trials of allopurinol and febuxostat before the plan approves pegloticase. Administrative delays can extend for weeks or months. If you are already on Original Medicare and develop severe gout requiring pegloticase, you cannot switch to Medigap during the year — you must wait for a valid enrollment period. This is why coverage decisions at age 65 carry long-term consequences for patients at risk of severe gout.

Does Medicare cover gout diet counseling? Not directly for gout. Medicare Part B covers medical nutrition therapy (MNT) for diabetes and kidney disease — if you have either comorbidity, your registered dietitian visits are covered and can address dietary uric acid management (limiting red meat, shellfish, alcohol, and high-fructose foods) as part of that covered benefit. General nutrition counseling specifically for gout without a qualifying comorbidity is not separately covered, though your rheumatologist or internist can address dietary modification during a standard covered office visit.